AbbVie Inc. (ABBV)
$283.48+3.32%Close
BUYBULL · day 23
Key stats
Short interest · FINRA settlement 2026-09-30
52-week IV7.4%–49.1%
- Market cap
- $500.9B
- Beta
- 0.28
- Div yield
- 3.02%
- P/E (TTM)
- 79.88
- IV-%ile
- 2
- IV ATM
- 15.3%
- Short % float
- 0.92%
- Days to cover
- 4.1
- SI change
- -16.5%
- 1W
- +4.47%
- 1M
- +7.77%
- vs SPY 1W
- +4.61%
- vs SPY 1M
- +5.26%
Industry peers
FMP comparable companies · ranked by market cap
- LLYBUYEli Lilly and Company$1.1TRECOVERYQ 21$1179.27+3.62%
- JNJSELLJohnson & Johnson$630.0BBEARQ 22$261.44+2.13%
- MRKSELLMerck & Co., Inc.$359.6BBEARQ 11$145.60+3.80%
- RHHBYRoche Holding AG$344.8B$54.09
- NVSBUYNovartis AG$273.2BRECOVERYQ 20$143.75+3.14%
- AZNSELLAstraZeneca PLC$246.9BRECOVERYQ 20$159.20+3.99%
- AMGNBUYAmgen Inc.$223.9BRECOVERYQ 22$414.87+3.21%
- PFEBUYPfizer Inc.$161.2BBULLQ 13$28.28+2.96%
- BMYSELLBristol-Myers Squibb Company$120.8BBEARQ 10$59.12+4.61%
- GSKSELLGSK plc$93.2BRECOVERYQ 14$46.50+3.46%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 27
- VALUE
- 0
- GROWTH
- 49
- GARP
- 41
- TYPE
- Dividend Compounder (blended)
Composite of Value · Growth · GARP
ROIC-81.9%
REV YoY-
ROE-136.5%
EPS YoY-
ROA4.7%
GROSS71
OP29
NET10
[VALUATION]
P/E TTM79.88
P/E FWD19.59
SECTOR PE20.48
INDUSTRY PE10.36
P/B-84.60
P/FCF-
EV/EBITDA26.68
EV/EBIT-
PEG2.29
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO0.81
ND/EBITDA-
BETA0.28
PAYOUT RATIO > 100% (189.7%)
Company news
FAQ
- What is LOPJLB’s current signal on ABBV?
- LOPJLB’s latest quantitative signal on AbbVie Inc. (ABBV) is BUY in a BULL regime. Signals are updated daily.
- What market regime is ABBV in?
- AbbVie Inc. (ABBV) is currently classified in the BULL HMM market regime on LOPJLB.
- What does AbbVie Inc. (ABBV) do?
- AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe p…